UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported): November 20, 2026 |
Acrivon Therapeutics, Inc.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware |
001-41551 |
82-5125532 |
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
|
480 Arsenal Way Suite 100 |
|
Watertown, Massachusetts |
|
02472 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
|
Registrant’s Telephone Number, Including Area Code: (617) 207-8979 |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading Symbol(s) |
|
Name of each exchange on which registered
|
Common Stock, par value $0.001 per share |
|
ACRV |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Safety, dose optimization, and early Phase 1/2 clinical results in AP3-predicted tumors for ACR-2316, a first-in-class WEE1/PKMYT1 inhibitor Timothy A. Yap1, Mohamad A. Salkeni2, Neel Gandhi3, Gerald Falchook4, David Sommerhalder5, Benedito A. Carneiro6, Judy Wang7, Monica Mita8, Kamlesh K. Sankhala9, Jeffery Russell10, David Levitz11, Lu Gan12, Besiana P. Beqo12, Kristina Masson12, Christina A. Scherer12, Erick Gamelin12, Eric Devroe12, Peter Blume-Jensen12, Mansoor R. Mirza12, Nicole Nevadunsky11 1 MD Anderson Cancer Center, Houston, TX, USA 2 NEXT Oncology – Virginia, Fairfax, VA, USA 3 Carolina BioOncology Institute, Huntersville, NC, USA 4 SCRI HealthONE, Denver, CO, USA 5 NEXT Oncology – San Antonio, San Antonio, TX, USA 6 Legorreta Cancer Center, Brown University, Providence, RI, USA 7 Florida Cancer Specialists / Sarah Cannon Research Institute, Sarasota, FL, USA 8 Hoag Memorial Hospital Presbyterian, Newport Beach, CA, USA 9 Precision NextGen Oncology & Research Center, Beverly Hills, CA, USA 10 Tennessee Oncology, Nashville, TN, USA 11 Montefiore Medical Center Einstein, Bronx, NY, USA 12 Acrivon Therapeutics, Inc., Watertown, MA, USA Exhibit 99.1

Disclosures Timothy A. Yap Employee of: University of Texas MD Anderson Cancer Center, where I am Vice President, Head of Clinical Development in the Therapeutics Discovery Division, which has a commercial interest in IACS-6274 and other inhibitors (IACS30380/ART0380 was licensed to Artios) Consultant for: AbbVie, Acrivon, Adagene, Almac, Aduro, Amphista, Artios, Astex, AstraZeneca, Athena, Atrin, Avenzo, Avoro, Axiom, Baptist Health Systems, Bayer, BeiGene, BioCity Pharma, Blueprint, Boxer, Bristol Myers Squibb, C4 Therapeutics, Calithera, Cancer Research UK, Carrick Therapeutics, Circle Pharma, Clovis, Cybrexa, Daiichi Sankyo, Dark Blue Therapeutics, Diffusion, Duke Street Bio, 858 Therapeutics, EcoR1 Capital, Ellipses Pharma, EMD Serono, Entos, F-Star, Genesis Therapeutics, Genmab, Glenmark, GLG, Globe Life Sciences, GSK, Guidepoint, Ideaya Biosciences, Idience, Ignyta, I-Mab, ImmuneSensor, Impact Therapeutics, Institut Gustave Roussy, Intellisphere, Jansen, Kyn, MEI pharma, Mereo, Merck, Merit, Monte Rosa Therapeutics, Nested Therapeutics, Nexys, Nimbus, Novocure, Odyssey, OHSU, OncoSec, Ono Pharma, Onxeo, PanAngium Therapeutics, Pegascy, PER, Pfizer, Piper-Sandler, Pliant Therapeutics, Prolynx, Radiopharma Theranostics, Repare, resTORbio, Roche, Ryvu Therapeutics, SAKK, Sanofi, Schrodinger, Servier, Synnovation, Synthis Therapeutics, Tango, TCG Crossover, TD2, Terremoto Biosciences, Tessellate Bio, Theragnostics, Terns Pharmaceuticals, Tolremo, Tome, Thryv Therapeutics, Trevarx Biomedical, Varian, Veeva, Versant, Vibliome, Voronoi Inc, Xinthera, Zai Labs, and ZielBio Grant/Research support from: Acrivon, Aprea, Artios, AstraZeneca, Bayer, BeiGene, BioNTech, Blueprint, Bristol Myers Squibb, Boundless Bio, Clovis, Constellation, Cyteir, Eli Lilly, EMD Serono, Forbius, F-Star, GlaxoSmithKline, Genentech, Haihe, Ideaya ImmuneSensor, Insilico Medicine, Ionis, Ipsen, Jounce, Karyopharm, KSQ, Kyowa, Merck, Mirati, Novartis, Pfizer, Ribon Therapeutics, Regeneron, Repare, Rubius, Sanofi, Scholar Rock, Seattle Genetics, Tango, Tesaro, Vivace, and Zenith.

WEE1 and PKMYT1 - critical cell cycle checkpoints in human cancer Defective DNA repair is highly prevalent in cancers, creating a dependency on S- and G2/M checkpoint proteins, such as WEE1 and PKMYT1 Acrivon Predictive Precision Proteomics (AP3) measures the global cellular effects of a drug on the protein signaling network in an unbiased manner AP3 was applied to design a highly differentiated, first-in-class WEE1/PKMYT1 inhibitor that activates CDK1, CDK2 as well as PLK1 to achieve potent single agent activity and high selectivity for improved Therapeutic Index

ACR-2316: uniquely designed by AP3 for superior therapeutic index over WEE1 and PKMYT1 inhibitors Drug Designed by AP3 to suppress resistance mechanisms A differentiated, potentially first-in -class WEE1/PKMYT1 inhibitor Designed for high selectivity for WEE1 and PKMYT1 to overcome resistance and to optimize safety Potent activation of CDK1, CDK2 as well as PLK1 to ensure strong mitotic catastrophe and tumor cell killing Complete tumor regression across all preclinical in vivo models Reciprocal quenching Intracellular activation (red) of CDK1, 2, and PLK1

Oral, once daily, 3-week cycles, until progression or unacceptable toxicity. Tumor assessments per RECIST v1.1 every 6 weeks. Study design and objectives Cohort A 3d on/4d off Cohort B 2d on/5d off 120 mg 160 mg AP3-identified, molecularly defined tumor types Dose Escalation – 2 intermittent QD oral regimens established (N = 33) 30 mg 200 mg 240 mg 120 mg 60 mg 240 mg 160 mg Randomized Dose Expansion: 3d on / 4d off ✅ ✅ Phase 1/2, first-in-human, open-label, multicenter study of oral ACR-2316 in advanced solid tumors Objectives (Dose escalation) Primary: MTD during 1st dosing cycle (21 days Cohort A/B) Secondary: safety and tolerability (TEAEs/TRAEs, CTCAE v5.0); PK of ACR-2316 and its metabolites Exploratory: antitumor activity – confirmed ORR (RECIST v1.1), DOR, CBR; PD markers in PBMCs; exposure–safety Key eligibility (Dose escalation) Advanced solid tumor progressed after ≥1 prior line; ≤3 prior lines for recurrent disease ECOG PS 0–1; measurable disease (RECIST v1.1); adequate organ function Tumor types: SCLC, sqNSCLC, adenoNSCLC, high-grade endometrial, ovarian, cervical, anal, vulvar, HPV+ oropharyngeal, small-cell neuroendocrine prostate; other tumors if p53 mutated

ACR-2316 Patient demographics and baseline characteristics Subject Demographics N = 33 Median age, years (range) 63 (35–77) Sex, n (%) Female 20 (60.6) Male 13 (39.4) Race, n (%) White 26 (78.8) Black/African American 3 (9.1) Asian 1 (3.0) Native Hawaiian/Pacific Islander 1 (3.0) Other/Unknown/Not Reported 2 (6.1) Cancer Type, n (%) N = 33 Endometrial 5 (15.2) Ovarian / fallopian tube 4 (12.1) Breast 4 (12.1) Adenocarcinoma NSCLC 3 (9.1) Colorectal 3 (9.1) Head & Neck SCC 3 (9.1) Squamous NSCLC 3 (9.1) Pancreatic / ampullary 2 (6.1) Prostate 2 (6.1) Small Cell Lung Cancer 2 (6.1) Urothelial 1 (3.0) Vulvar 1 (3.0) ECOG at Baseline, n (%) N = 33 0 10 (30.3) 1 23 (69.7) Prior Therapy Lines, n (%) 1 1 (3.0) 2 5 (15.2) 3 14 (42.4) 4 7 (21.2) 5 1 (3.0) ≥6* 5 (15.2) Median prior lines (range) 3 (1–8) Prior IO Therapy, n (%) Yes 25 (75.8) No 8 (24.2) * ≥6 prior lines: 3 with 6, 1 with 7, 1 with 8. Data cut-off 02-Nov-2026; non-QC’d EDC data.

ACR-2316 Safety: treatment-related adverse events Grade ≥3 TRAEs (≥5% overall) – Dose-escalation population, Cohort A 120 mg and 160 mg Grade ≥3 TRAEs Overall N = 33 (Cohorts A and B) Cohort A 120 mg (n = 4) Cohort A 160 mg (n = 4) Grade 3 n (%) Grade 4 n (%) Grade ≥3 n (%) Grade 3 n (%) Grade 4 n (%) Grade ≥3 n (%) Grade 3 n (%) Grade 4 n (%) Grade ≥3 n (%) Neutropenia 5 (15.2) 10 (30.3) 15 (45.5) 1 (25.0) 0 1 (25.0) 1 (25.0) 0 1 (25.0) Leukopenia 3 (9.1) 4 (12.1) 7 (21.2) 0 0 0 0 0 0 Anemia 6 (18.2) 0 6 (18.2) 1 (25.0) 0 1 (25.0) 0 0 0 ALT increased 2 (6.1) 0 2 (6.1) 0 0 0 1 (25.0) 0 1 (25.0) Lymphopenia 2 (6.1) 0 2 (6.1) 0 0 0 0 0 0 TOTAL unique subjects 15 (45.5) 11 (33.3) 19 (57.6) 2 (50.0) 0 2 (50.0) 2 (50.0) 0 2 (50.0) TRAE = treatment-related adverse event (related or possibly related); worst CTCAE v5.0 grade per subject. Highly differentiated, favorable safety profile Grade ≥3 AEs were predominantly asymptomatic, transient, mechanism-based neutropenia and leukopenia No non-hematological DLTs, no febrile neutropenia, and no Grade 5 AEs were observed Data cut-off 02-Nov-2026; non-QC’d EDC data.

TRAE = treatment-related adverse event; DLT = dose-limiting toxicity. Dose interruption includes delays and holds. Dose-escalation population (N = 33), Cohort A 120 mg and 160 mg Tolerability of ACR-2316 Tolerability endpoints n (%) Overall N = 33 120 mg n = 4 160 mg n = 4 Any TRAE 26 (78.8) 3 (75.0) 3 (75.0) Grade 3 TRAE 8 (24.2) 2 (50.0) 2 (50.0) Grade 4 TRAE 11 (33.3) 0 0 Serious TRAE 5 (15.2) 0 0 TRAE → dose interruption 19 (57.6) 2 (50.0) 2 (50.0) TRAE → dose reduction 8 (24.2) 0 1 (25.0) TRAE → discontinuation 1 (3.0) 0 0 DLT /DLT-evaluable 8/29 (27.6) 0/4 (0.0) 0/3 (0.0) No Grade 4 TRAEs or DLTs observed at 120 or 160 mg (Cohort A; 3 on / 4 off) All DLTs were neutropenia at doses >160 mg (no febrile neutropenia) 120 and 160 mg selected for randomized dose expansion (Project Optimus) Data cut-off 02-Nov-2026; non-QC’d EDC data.

Favorable dose-proportional PK of ACR-2316 with minimal accumulation T1/2 ~ 12h

Drug target engagement of ACR-2316 in patient PBMCs from 1st dose level (AP3 MS assay) CDK1 CDK2 (QxxxxxxS/TPxxKxxx) CDK5 (xTxxxxxS/TPxxxxEx) PLK1 (xxxxLDxS/TxxExxxx) AKT1 (xxRxRxxS/TxSxxxxx) AKT2 (xxxxRxxS/TxSxxxxx) Drug-regulated P-sites (paired t-test : p-value < 0.05) (xxxxxxxS/TPxK/RxxSx) N=32196 Phosphosites identified from MS-proteomics CDK1_substrate1 AKT1_substrate14 AKT2_substrate10 Pre-Dose vs Post-Dose of specific substrates CDK2_substrate1 CDK5_substrate1 PLK1_substrate1 N=125 Drug-regulated substrates of key kinases AP3 Consistent with compound design, CDK1, 2 and PLK1 most upregulated, and AKT1/2 most downregulated kinases

Promising clinical activity of ACR-2316 observed at doses ≥120 mg Weeks on Treatment (N =25) Best Tumor Shrinkage Best % Change from Baseline % Change in Target Lesions from Baseline Target Lesion Change Over Time Subjects dosed at ≥120 mg with ≥1 on treatment scan (N =25) Off Treatment On Study SqNSCLC Molecular profile: BRCA1 p.L392fs (germline susp.), TP53 p.H179L, FGFR1 gain; PD-L1 TPS <1%, MSS, TMB 4.5 mut/Mb Prior lines (3) 1) carbo/tax + RT → durva 2) pembro → nivo + ipi 3) PD-1×PD-L1 bispecific Confirmed CR · 160 mg Endometrial Molecular profile: MSS, PTEN, BRCA1/2wt, TP53wt, POLεwt; no tumor NGS Prior lines (4) 1) carbo/tax 2) carbo/tax 3) tamoxifen 4) pembro + lenva Confirmed PR (-41%)· 120 mg SCLC Molecular profile: TP53 p.E286V, RB1 loss, FGFR2 p.M538I (activating); MSS, TMB 7.4 mut/Mb (low) Prior lines (3) 1) cis/etop + RT 2) durva 3) tarlatamab Unconfirmed PR (-69%)· 160 mg Data cut-off 02-Nov-2026; non-QC’d EDC data.

Durable clinical activity of ACR-2316 in heavily pretreated lung cancer patients % Change in Target Lesions (On-Treatment Scans) Duration of Last Prior Therapy and Time on ACR-2316 by Patient 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 adNSCLC-01 adNSCLC-02 adNSCLC-03 sqNSCLC-01 sqNSCLC-02 SCLC-01 SCLC-02 12 71 9 71 42 7 26 60 6 26 9 5 20 13 SD; On treatment Weeks on last prior line Weeks on ACR-2316 CR; Off treatment, on study Weeks on treatment 1 Year 7 Lung Cancer Patients (≥120 mg) Squamous NSCLC: confirmed CR and CMR (FDG-PET) on study >65 weeks AdenoNSCLC: 2 patients with SD, on treatment >71 weeks Squamous NSCLC: SD >25 weeks SCLC: deep tumor shrinkage (uPR) Tumor type SCLC Sq. NSCLC Ad. NSCLC RECIST 1.1 CR PR SD PD Weeks on treatment 1 Year Data cut-off 02-Nov-2026; non-QC’d EDC data.

ACR-2316: Conclusions Highly differentiated, potentially first-in-class oral WEE1/PKMYT1 inhibitor Rationally designed with the AP3 platform for superior single-agent activity through dual Wee1/PKMYT1 inhibition and activation of not only CDK1 and CDK2, but also PLK1 Favorable safety profile Predominantly limited to transient, asymptomatic, mechanism-based neutropenia – with no Grade 4 or 5 treatment-related events and no DLTs at the selected 120 mg and 160 mg doses Durable single-agent activity with long-lasting clinical benefit 5/7 pts with lung cancer, an AP3-predicted tumor type not typically sensitive to WEE1i or PKMYT1i, experienced clinical benefit 1 confirmed CR (SqNSCLC; on study >65 wks) 3 SD (2 adenoNSCLC; on treatment >71 wks; 1 SqNSCLC; >25 weeks) 1 unconfirmed PR with deep tumor shrinkage (SCLC) Confirmed PR >40 weeks in pt with endometrial cancer Two optimized doses advancing in randomized expansion in AP3-predicted tumor types 120 mg and 160 mg, 3 days on / 4 days off, selected to support RP2D and further development (NCT06667141)

ACR-2316: Acknowledgments To our patients and their families Our deepest gratitude goes to every patient who has taken part, and continues to take part, in this study, and to the families and caregivers who stand beside them. Your trust, courage and generosity are the foundation of everything we are learning. We are humbled to share this journey with you! To our investigators and site teams We are sincerely grateful to all the principal investigators, sub-investigators, study coordinators, research nurses, pharmacists and data managers at every participating site. Their dedication and meticulous work make this trial possible. Thank you for your continued partnership! To the entire Acrivon team for their commitment and hard work in bringing ACR-2316 to patients. Thank you! This study (NCT06667141) is ongoing and currently enrolling in the dose-expansion phase. Sponsored by Acrivon Therapeutics, Inc.